Annuncio • Oct 28
Uscom Limited, Annual General Meeting, Nov 27, 2025 Uscom Limited, Annual General Meeting, Nov 27, 2025. Location: at suite 2, level 8, 66 clarence street, sydney Australia Reported Earnings • Sep 30
Full year 2025 earnings released: AU$0.018 loss per share (vs AU$0.012 loss in FY 2024) Full year 2025 results: AU$0.018 loss per share (further deteriorated from AU$0.012 loss in FY 2024). Revenue: AU$2.58m (down 31% from FY 2024). Net loss: AU$3.30m (loss widened 59% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.018 loss per share (vs AU$0.012 loss in FY 2024) Full year 2025 results: AU$0.018 loss per share (further deteriorated from AU$0.012 loss in FY 2024). Revenue: AU$3.16m (down 15% from FY 2024). Net loss: AU$3.30m (loss widened 59% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Board Change • Aug 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jan 31
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Market cap is less than US$10m (AU$7.51m market cap, or US$4.67m). Minor Risk Revenue is less than US$5m (AU$3.7m revenue, or US$2.3m). Board Change • Jan 07
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Sep 24
Uscom Limited, Annual General Meeting, Oct 25, 2024 Uscom Limited, Annual General Meeting, Oct 25, 2024. Location: suite 2 level 8, 66 clarence street, sydney Australia Reported Earnings • Aug 30
Full year 2024 earnings released: AU$0.012 loss per share (vs AU$0.015 loss in FY 2023) Full year 2024 results: AU$0.012 loss per share (improved from AU$0.015 loss in FY 2023). Revenue: AU$4.21m (up 58% from FY 2023). Net loss: AU$2.07m (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. New Risk • Aug 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (AU$3.24m market cap, or US$2.20m). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (31% increase in shares outstanding). Revenue is less than US$5m (AU$3.4m revenue, or US$2.3m). New Risk • Mar 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (AU$5.19m market cap, or US$3.38m). Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (AU$3.4m revenue, or US$2.2m). Reported Earnings • Feb 09
First half 2024 earnings released: AU$0.005 loss per share (vs AU$0.008 loss in 1H 2023) First half 2024 results: AU$0.005 loss per share (improved from AU$0.008 loss in 1H 2023). Revenue: AU$1.96m (up 56% from 1H 2023). Net loss: AU$900.7k (loss narrowed 35% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year whereas the company’s share price has fallen by 40% per year. Annuncio • Feb 05
Uscom Limited has filed a Follow-on Equity Offering in the amount of AUD 2.014212 million. Uscom Limited has filed a Follow-on Equity Offering in the amount of AUD 2.014212 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 54,438,159
Price\Range: AUD 0.037
Discount Per Security: AUD 0.00111
Transaction Features: Rights Offering Board Change • Jan 31
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jan 02
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Nov 22
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Oct 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Sep 25
Uscom Limited, Annual General Meeting, Oct 26, 2023 Uscom Limited, Annual General Meeting, Oct 26, 2023, at 11:30 AUS Eastern Standard Time. Location: Suite 2, Level 8, 66 Clarence Street Sydney New South Wales Australia Agenda: To receive and consider the Financial Report of the Company together with the reports of the Directors and the Auditor for the financial year ended 30 June 2023; to approve adoption of Remuneration Report for the Year Ended 30 June 2023; to approve re-election of Director, Mr. Xianhui Meng; to approve grant of Share Rights to Executive Chairman Rob Phillips; and to approve additional Share Issue Capacity under Listing Rule 7.1A. Board Change • Sep 19
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Aug 31
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. New Risk • Aug 19
New major risk - Revenue and earnings growth Earnings have declined by 7.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Market cap is less than US$10m (AU$9.91m market cap, or US$6.35m). Minor Risk Revenue is less than US$5m (AU$3.2m revenue, or US$2.0m). Reported Earnings • Aug 18
Full year 2023 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2022) Full year 2023 results: AU$0.015 loss per share (further deteriorated from AU$0.011 loss in FY 2022). Revenue: AU$3.16m (down 3.0% from FY 2022). Net loss: AU$2.59m (loss widened 31% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings. Board Change • Jul 07
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • May 09
Uscom Limited (ASX:UCM) announces an Equity Buyback for 19,676,833 shares, representing 9.91% for AUD 1.08 million. Uscom Limited (ASX:UCM) announces a share repurchase program. Under the program, the company will repurchase up to 19,676,833 shares, representing 9.91% of its issued share capital. The shares will be repurchased at a price of AUD 0.055 per share. The purpose of the offer is to to optimize shareholder's value. Shares will be repurchased using company's current cash reserves. The record date for the offer is May 12, 2023. The offer will close on June 15, 2023. As of May 8, 2023, the company had 198,635,884 shares issued. Board Change • Apr 11
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.008 loss per share (vs AU$0.006 loss in 1H 2022) First half 2023 results: AU$0.008 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$1.26m (down 22% from 1H 2022). Net loss: AU$1.39m (loss widened 48% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Sep 30
Uscom Limited, Annual General Meeting, Nov 10, 2022 Uscom Limited, Annual General Meeting, Nov 10, 2022, at 11:30 AUS Eastern Standard Time. Location: Suite 2, Level 8, 66 Clarence Street Sydney New South Wales Australia Agenda: To Adopt the Remuneration Report; to re-elect Mr. Brett Crowley as a Director; to consider ratification of Private Placement of Shares in 1 April 2022; to consider ratification of Private Placement of Shares in 5 July 2022; to grant of Share Rights to Executive Chairman Rob Phillips; and to consider approval of additional Share Issue Capacity under Listing Rule 7.1A. Reported Earnings • Aug 19
Full year 2022 earnings released: AU$0.011 loss per share (vs AU$0.006 loss in FY 2021) Full year 2022 results: AU$0.011 loss per share (down from AU$0.006 loss in FY 2021). Revenue: AU$3.25m (down 29% from FY 2021). Net loss: AU$1.97m (loss widened 113% from FY 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Christian Bernecker was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Feb 24
Uscom Limited to Be Deleted from Other OTC Uscom Limited's SHS (Australia) will be deleted from Other OTC effective February 23, 2022. The deletion is due to Inactive Security. Annuncio • Sep 24
Uscom Limited Releases Details of A Study Confirming the High Accuracy of the Uscom BP+ Central Blood Pressure Monitor Uscom Limited released details of a study confirming the high accuracy of the Uscom BP+ central blood pressure monitor for detection of the dangerous cardiac rhythm abnormality Atrial Fibrillation (AF) in a primary care setting. This results confirms that BP+ suprasystolic oscillometry is 94% effective for detection of AF in home care environments and may be used as a screening investigation. AF is a common cardiac dysrhythmia occurring in approximately 40m adults worldwide. However AF is associated with significant mortality and morbidity from stroke and heart failure and is often undiagnossed. The presence of AF may warrant the use of prophylactic anticoagulation, which is also associated with additional complications, making the accurate and cost effective detection of AF an important health screening procedure. This study compared Uscom BP+ suprasystolic oscillometric detection of AF with a 12 lead ECG interpreted by a senior cardiology consultant and found an accuracy of 90% for BP+ measures with an overall effectiveness of 94%. Concurrent comparison of a hand held phone with a dual lead ECG attached for detection of AF demonstrated an accuracy of 73%. The Uscom BP+ examination can be performed in approximately 60 seconds by a technician while the 12 lead ECG takes in the order of 15-30 minutes and requires a consultant cardiologist for interpretation. The BP+ suprasystolic monitor is a specialised technology for diagnosis and therapeutic guidance in hypertension and vascular health. The accurate detection of AF as part of the current BP examination using the BP+ suprasystolic oscillometer expands the utility and application of the technology, and simplifies the primary care assessment of cardiovascular risk. The BP+ technology is simple to operate and provides rapid and accurate results, from 58 measures of blood pressure and cardiovascular performance, compared to the 6 presented in current simple BP monitors. Reported Earnings • Aug 22
Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.009 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$4.55m (up 6.3% from FY 2020). Net loss: AU$924.2k (loss narrowed 31% from FY 2020). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Annuncio • Aug 13
Uscom Limited Announces Five New Software Copyrights for BP Plus in China Uscom Limited notified the market that Uscom China has recently received five new software copyrights covering the core performance and function of the Uscom BP+ central BP monitor. These approvals consolidate Uscom's IP strategy in China taking the current accepted and submitted patents, copyrights and trademarks in China to 42. Hypertension is the leading modifiable risk factor for cardiovascular disease and death and occurs in approximately 1/3 of all Chinese adults and is associated with a with a 4 times incidence of cardiovascular disease and mortality. In China less than 50% of hypertensive patients are treated, and of these less than 30% have effective BP control, with an overall control rate of 4.2%. The new BP+ suprasystolic oscillometric technology allows for more precise monitoring of the blood pressure in the arms and in the heart, resulting in improved therapy and outcomes, and is an important advancement for both Uscom and hypertensive and vascular care in China. The NMPA approved the sale of BP+ in April 2021. Recent Insider Transactions • Jun 30
Founder recently bought AU$102k worth of stock On the 28th of June, Robert Phillips bought around 645k shares on-market at roughly AU$0.16 per share. In the last 3 months, there was an even bigger purchase from another insider worth AU$145k. This was Robert's only on-market trade for the last 12 months. Annuncio • May 29
Uscom Limited Announces Two New USCOM Monitors Get Australian Tga Clearance SUscom Limited announced the market that Uscom has received Therapeutic Goods Administration (TGA) issued Free Sales Certificates for two new haemodynamic monitoring devices. TGA clearance was for the USCOM O2 and USCOM Basic monitors, specialised forms of the USCOM 1A non-invasive ultrasound Doppler hemodynamic monitor. Recent Insider Transactions • May 29
Non-Executive Director recently bought AU$145k worth of stock On the 25th of May, Xianhui Meng bought around 1m shares on-market at roughly AU$0.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$182k more in shares than they have sold in the last 12 months. Annuncio • May 25
Uscom Limited Announces SpiroSonic Air Approved for European Ce Mark Uscom Limited announced the market of notice to approve CE mark for the Uscom digital ultrasonic SpiroSonic AIR spirometer. The CE mark is recognition of legal compliance with health, safety and environmental standards set by the European community, and is essential for sale of new medical technologies into the European Economic Area and many SE Asian jurisdictions, a market with a combined population of ~1.4B people. The SpiroSonic AIR is the leading technology in spirometry utilising Uscom's patented multi-path digital ultrasonic technology, wireless induction charging and BT4 wireless communications. The SpiroSonic AIR connects wirelessly to the mobile phone loaded MyAIR, and SpiroReporter software allowing for remote telemetric and cloud-based diagnosis and monitoring and home care. The BT4 capability will allow simple connection to Uscom's cloud based Blue Sky eHealth Ecosystem, providing a new pay per use digital revenue source. Annuncio • May 04
Uscom Limited Announces Two New Uscom Devices for China Uscom Limited completed the development of two new specialised cardiovascular monitors, the "USCOM O2" and the "USCOM Basic". The development of these two new monitors creates for Uscom a three-tier range of Uscom haemodynamic monitors for sale into China. Uscom is required to obtain regulatory approval of the China National Medical Products Administration (NMPA) for the two new specialised cardiovascular monitors prior to the commencement of sales. The NMPA process involves 9 steps including document writing, collection, translation, review and product testing, and is estimated to take 12 months for approval, if milestones are achieved according to guidelines. Reported Earnings • Feb 25
First half 2021 earnings released: AU$0.002 loss per share (vs AU$0.011 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$2.74m (up 184% from 1H 2020). Net loss: AU$269.7k (loss narrowed 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Annuncio • Sep 19
Uscom Limited Appoints MedCaT as New European Distributor Uscom Limited announced the appointment of MedCaT as an USCOM 1A distributor for the Netherlands. MedCaT is a part of the Feles Medici group delivering sophisticated neurologic and cardiovascular devices into the Netherlands and Germany. Distribution and sales lead directly to revenue, and are the key to business. Annuncio • Aug 29
Uscom Limited announced that it has received funding Uscom Limited (ASX:UCM) announced a private placement of 300,000 common shares on August 28, 2020. The transaction involved participation from Nicholas Schicht, General Manager of teh company. 